DNAY News and Press, Codex DNA Inc. From 08/10/21

Codex DNA, Inc. (DNAY) Q2 2021 Earnings Conference Call August 10, 2021 05:00 PM ET Company Participants Jennifer McNealey - Chief Financial Officer Todd Nelson - Chief Executive Officer Dan Gibson - Chief Technology Officer Conference Call Participants Paul Knight - KeyBanc Brandon Couillard...

SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2021. “During the second quarter, Codex DNA took a big step forward in ...

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a collaboration with researchers from the U.S. Department of Agriculture’s (USDA) Agricultural Research Service (ARS), Cornell Unive...

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 financial results on Tuesday, August 10, 2021. Company management will host a conference cal...

libre de droit/iStock via Getty Images Codex DNA ([[DNAY]] +7.4%) signed a licensing and supply agreement with Maravai LifeSciences' ([[MRVI]] +1.8%) TriLink Biotechnologies division for the latter's CleanCap technology. Codex DNA will integrate the mRNA capping technology into its suite...

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ: MRVI), for its industry-leading CleanC...

Shares of Codex DNA Inc. (NASDAQ:DNAY) traded today at $14.61, breaking its 52-week low. So far today approximately 205,000 shares have been exchanged, as compared to an average 30-day volume of 227,000 shares. Codex DNA Inc is a synthetic biology company focused on enabling researchers ...

Shares of Codex DNA Inc. (NASDAQ:DNAY) traded at a new 52-week low today of $15.41. Approximately 205,000 shares have changed hands today, as compared to an average 30-day volume of 218,000 shares. Codex DNA Inc is a synthetic biology company focused on enabling researchers to rapidly, a...

adrian825/iStock via Getty Images Psychedelic drug developers started as buys Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald have initiated Atai Life Sciences ([[ATAI]] +2.3%) with  buy/overweight ratings. Credit Suisse has a $25 price target on shares (~35% upside) Credit...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead It's that time again, as second-quarter earnings season kicks off in earnest with the usual early reports from banks - J...